One-step radiosynthesis of 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 9, 2011, Pages 1732-1741

  Liu, Shuanglong ^a   Liu, Hongguang ^a   Jiang, Han ^a,b   Xu, Yingding ^a   Zhang, Hong ^b   Cheng, Zhen ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

18F; Aluminum fluoride; Integrin v 3; Molecular imaging; NOTA; PET; RGD dimer

Indexed keywords

ALUMINUM FLUORIDE 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID ARGININE GLYCINE ASPARTIC ACID F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; DIAGNOSTIC AGENT; HETEROCYCLIC COMPOUND; INTEGRIN; OLIGOPEPTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHELATION; CONTROLLED STUDY; FEASIBILITY STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; ONE STEP RADIOSYNTHESIS; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RECEPTOR BINDING; TUMOR ANGIOGENESIS; TUMOR XENOGRAFT; ANIMAL; BLOOD; CHEMISTRY; DRUG STABILITY; FEMALE; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS; INTEGRINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY;

EID: 80955178858     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1847-4     Document Type: Article

References (31)

1. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
2. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-23.
3. Klein CA. Cancer. The metastasis cascade. Science 2008;321:1785-7.
4. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008;321:1841-4.
5. Kumar CC. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-31. (Pubitemid 36553584)
6. Jacobson O, Zhu L, Niu G, Weiss ID, Szajek LP, Ma Y, et al. MicroPET imaging of integrin α (v) β (3) expressing tumors using (89) Zr-RGD peptides. Mol Imaging Biol 2010.
7. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010;37 Suppl 1:S86-103.
8. Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, et al. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. Nucl Med Biol 2010;37:727-40.
9. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-5. (Pubitemid 32691983)
10. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-41. (Pubitemid 43733484)
11. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
12. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 2009;50:116-22.
13. McParland BJ, Miller MP, Spinks TJ, Kenny LM, Osman S, Khela MK, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49:1664-7.
14. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879-86. (Pubitemid 351793427)
15. Wu Z, Li ZB, Cai W, He L, Chin FT, Li F, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34:1823-31. (Pubitemid 47599045)
16. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: (18) F-labeled RGD and octreotide analogs. J Nucl Med 2004;45:892-902. (Pubitemid 47618571)
17. Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido) ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αvβ3 integrin expression. J Nucl Med 2006;47:1172-80. (Pubitemid 47544912)
18. Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, et al. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem 2008;19:1871-9.
19. Höhne A, Yu L, Mu L, Reiher M, Voigtmann U, Klar U, et al. Organofluorosilanes as model compounds for 18F-labeled siliconbased PET tracers and their hydrolytic stability: experimental data and theoretical calculations (PET=positron emission tomography). Chemistry 2009;15:3736-43.
20. Ting R, Harwig C, auf dem Keller U, McCormick S, Austin P, Overall CM, et al. Toward [18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J Am Chem Soc 2008;130:12045-55.
21. Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, et al. A novel facile method of labeling octreotide with (18) F-fluorine. J Nucl Med 2010;51:454-61.
22. McBride WJ, D'Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, et al. Improved 18F labeling of peptides with a fluoridealuminum-chelate complex. Bioconjug Chem 2010;21:1331-40.
23. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, et al. A novel method of 18F radiolabeling for PET. J Nucl Med 2009;50:991-8.
24. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, et al. microPET imaging of glioma integrin αvβ3 expression using (64) Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707-18. (Pubitemid 46211595)
25. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, et al. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol 2010;12:530-8.
26. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin αvβ3 expression in living mice. Bioconjug Chem 2005;16:1433-41. (Pubitemid 41681509)
27. Mittra E, Goris ML, Lagaru AH, Kardan A, Burton L, Berganos R, et al. Pilot pharmacokinetic and dosimetric studies of [18F] FPPRGD2: A PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology. In press 2011.
28. de Bruin B, Kuhnast B, Hinnen F, Yaouancq L, Amessou M, Johannes L, et al. 1-[3-(2-[18F]fluoropyridin-3-yloxy) propyl] pyrrole-2, 5-dione: design, synthesis, and radiosynthesis of a new [18F]fluoropyridine-based maleimide reagent for the labeling of peptides and proteins. Bioconjug Chem 2005;16:406-20. (Pubitemid 40388217)
29. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, Liu H, et al. Evaluation of a (64) Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing αvβ3 integrin. J Nucl Med 2010;51:251-8.
30. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer alpha vintegrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41-9. (Pubitemid 38165979)
31. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64) Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J Nucl Med 2007;48:1162-71. (Pubitemid 47052657)